John Mackey a Siemens industry expert is dedicated to sustainability and innovation of the British & Irish industrial sector. Drawing from his diverse Siemens experience, he leverages digitalization technology to address industry challenges. John holds a degree in Physics from the University of Leeds and has been at Siemens for 5 years, starting as a graduate engineer moving on to product management and now a sales specialist in factory automation software. In his current role he works across different industry verticals to aid the adoption of technologies such as simulation, Edge and IOT to tackle the big challenges in industry. As a speaker, he illuminates Siemens' role in empowering customers to embrace sustainability through digitalization, transforming design, manufacturing, and services.

Alison Caldwell is a Group Leader in Analytical Development at Resolution
Therapeutics.  Resolution Therapeutics are a macrophage cell therapy company
focused on resolving chronic inflammatory damage.  As a Group Leader in Analytical
Development Alison is involved in leading the development of analytical methods to
support CMC activities for early and late-stage clinical products.  Prior to joining
Resolution Therapeutics Alison gained experience as a Principal Scientist in R&D at
Quotient Ltd. and a Senior Study Director at Charles River Laboratories.

Simon has 25 years in Information Technology & Digital leadership in the Biopharma industry with particular focus on manufacturing and supply chain digital transformation. Experience has been gained at major global leaders - Eli Lilly, Pfizer and most recently AstraZeneca. This has spanned the globe with extensive experience in the Asia Pacific region, including Japan and China, and more recently throughout Europe and the USA.

Simon was the global lead for AstraZeneca 'Smart Factories' strategy, embracing Industry 4.0/5.0 concepts to transform its strategic factories across the globe to deliver value for people, patients, and the planet. Simon is regarded as one of the global leaders in Manufacturing & Supply Chain Digital Transformation.

Simon is the founder and CEO of global boutique consultancy, Liminos, which is focused on technology enabled business transformations in life sciences manufacturing and supply chain.

Steven has over 30 years experience in Pharmaceuticals, Biologics and Consumer Healthcare manufacturing, specialising in project delivery and technology development. Steven has recently joined DTG as Chief Technology Officer, following his previous role as Head of GSK manufacturing execution systems.

Dr Ian Archer is currently the CEO of the new BioConnect Ireland Innovation Centre. He was previously the Technical Director of Scotland’s Industrial Biotechnology Innovation Centre from 2015 to 2023 where he was responsible for directing the technical strategy of the Centre and its Skills programme. Ian spent 11 years with Ingenza from 2004 after spending 6 years as a Work Group Leader in Process Technology with Zeneca (latterly Avecia) in Grangemouth, Scotland. He received his degree and PhD in chemistry from Imperial College, London.

His technical background is in synthetic organic chemistry and chemical process development. He developed expertise at the interface of molecular biology, microbiology and bioprocess development while Head of Process Development at Ingenza where he was responsible for all aspects of bioprocess development. More recently Ian has developed expertise in supporting companies on various elements of their innovation journeys from techno-economic analysis and carbon accounting to skills strategy.

Ed is a leader with vision who drives innovation and change with the fortitude and energy to deliver his vision. He challenges assumptions, raises ambitions and finds new ways of tackling complex issues locally and globally.

Ed has spent almost 30 years driving positive change in emerging industries- digital transformation of Scotlands enterprise system and SMEs and more recently the transition to a net zero carbon society.

Ed a serial entrepreneur and intrapreneur, has worked within the university sector for over 20 years -always with a strong focus on impact- bringing the public, academic and commercial sectors together to develop new pathways and mechanisms to deliver major strategic initiatives. His efforts led to founding of ECCI, and China’s first Low Carbon College and 30 other initiatives and has supported hundreds of SME leadership teams, over 1000 businesses and organisations to adapt and thrive as part of Scotland’s green eco-system.

Ed is a well known public speaker and thought leader in SME business models, innovation systems and sustainability. Ed holds a number of board and advisory positions nationally and globally and in 2021 Ed was awarded an honorary professorship of the university of edinburgh for his contribution and impact nationally and globally in driving partnerships and solutions to address the climate crisis.

Fernanda is the Head of Manufacturing Innovation and Partnerships at CGT Catapult. Working
alongside the rest of the collaborations team, she focuses on identifying industry challenges and
putting together multi-party collaborations to address these grand challenges. Her interest is
heavily on manufacturing innovation and helping the industry to really push the limits in
development, adoption and deployment of new manufacturing technology. She works closely with
the Manufacturing Innovation Centres (MICs) as well as with the wider teams in CGT Catapult.
Fernanda is a Chemical Engineering with a Masters and PhD in Biochemical Engineering from
University College London (UK). As Head of Manufacturing Innovation for Cell and Gene Therapy
Catapult she helps deliver exciting projects that aim to accelerate implementation and
deployment of innovative technology with the ultimate goal of more ATMPs reaching the market
and increased patient access. She’s interested in novel tools and technologies which span from
automation and control to digital emerging technologies as well as new services.

Keith is a Fellow of the IChemE with over 38 years’ experience in the analysis, design and specification of automation systems across a wide range of industries, including pharmaceuticals, food, polymers, chemicals,
petrochemicals, oil and gas production. He is a committee member of the IChemE Process Management and Control Subject Group. Keith has been involved in all phases the automation project life cycle from requirements gathering, conceptual design & consultancy to testing and validation, he has extensive working experience with various DCS, PLC, SCADA, and MES systems. Keith is an active member of the BioPhorums Plug and Play group who are developing interoperability standards for Biopharmaceutical equipment with the aim of standardizing equipment operation and simplifying integration. This approach is expected to significantly reduce the cost of design and building Biopharmaceutical facilities and offer a significant reduction in the configuration of the manufacturing equipment. Keith is a specialist in the PM Group Smart Manufacturing Group, providing analysis of Smart Manufacturing requirements and technical support to PM Group Operations and Business Development.

Kevin is the Chief Technology and Strategy Officer at RoslinCT, an Edinburgh based company now with
operations in Boston, manufacturing highly innovative and disruptive cell and gene therapies,
including the recently announced World’s first CRISPR gene edited cell therapy for sickle cell disease
and β-Thalassemia, Casgevy. Kevin has over 20 years’ experience in the biotech industry, with a
focus on pre-clinical and clinical development and manufacture of cell therapies, particularly with
pluripotent stem cells.
As Chief Operating Officer at RoslinCT, he oversaw the company’s growth from 50 to 220 staff,
establishment of a new manufacturing facility and acquisition of the company’s commercial
manufacturing licence from the MHRA. In his current role he is responsible for developing and
enhancing the company’s services and capabilities by leading the technology vision and strategy.

Highlands and Islands Enterprise's purpose is to build and sustain a greener, fairer and more resilient region that benefits everyone. HIE recognises that life sciences, digital health and social care, alongside marine biotechnology and aquaculture, are regional transformational opportunities. Much of Elaine's time is spent collaborating with partner organisations to create conditions that enable sustainable business growth in the Highlands and Islands. Elaine is also responsible for ensuring the region benefits from recent significant investments including the Inverness Campus, the Life Science Innovation Centre and the European Marine Science Park.

Dr Eve Hanks is CEO & Founder of MI:RNA Diagnostics. She is a veterinary surgeon with a certificate in medicine and a PhD in immunology and is responsible for the conception of MI:RNA’s groundbreaking new diagnostic testing platform. As a solo female founder, Dr Hanks grew the business from the ground up and maintains oversight of the technology development while leading a team of ambitious entrepreneurial innovators, creating a new wave of veterinary diagnostics using cutting-edge science. MI:RNA are ready to revolutionise the diagnostic market to protect animal welfare and give us more time with our pets.

Since joining Ingenza in 2004, Reuben has spearheaded the company’s core technology development delivering numerous proprietary bioprocesses which has underpinned growth of the company to date. By utilising Ingenza’s world class biotechnology expertise, Reuben has delivered, on time and on budget, commercial projects spanning carbon capture utilisation, biobased chemical production, small molecule API production, medical diagnostics and many others. Reuben has a strong portfolio in securing investment in mixed private/public and commercial partnerships over many years which has enabled in house and customer technology development. Reuben plays an integral role in the mentorship of staff at Ingenza and his leadership is founded on a true passion for chemical, life and biomedical sciences which drives his lateral thinking and innovative approach to resolving the needs of Ingenza’s customers

Jon-Paul Sherlock is Executive Director, Manufacturing Technology Strategy. He is responsible for the development and introduction of new manufacturing technologies that improve quality and process robustness, supply chain agility, reduce costs and ensure the AstraZeneca Global Operations supply network is fit for the future. He has a PhD in Chemical Engineering, is a chartered chemical engineer, Fellow of Royal Academy of Engineering and has over 25 years’ experience of pharmaceutical Research and Development. Jon-Paul has created links between industry and academia founding significant collaborations in formulation, physical processing and advanced manufacturing technologies. He is a Visiting Professor at the Universities of Manchester, Strathclyde and Leeds, is a member of the MMIC Leadership Team and is a member of Life Sciences Scotland Industry Leadership Group

Dr Soumya Palliyil is the head of Scottish Biologics Facility where she runs several antibody discovery and development projects with academic and commercial partners. As CEO and co-founder she is currently leading the creation of BrIgID Biologics, a novel antifungal biologics spin-out company from the University of Aberdeen supported by the Scottish Enterprise -High Growth Spinout Programme. Soumya completed her MRes and PhD at the University of Aberdeen and was the award-winning associate for the best Knowledge Transfer Partnership in Scotland (2011). She received the Royal Society of Edinburgh Commercialisation Fellowship and recently came runner-up at the Converge Challenge 2023 main prize category for BrIgID Biologics.

Mark has spent 30 years in roles within the health sector including biologicals/pharmaceuticals, medical technology and consultancy. In February 2022 Mark became Co Chair of the Life Sciences Industrial Leadership Group in Scotland, he also continues to support decision making for non-medicine technologies through membership of the Scottish Health Technology Group plus as a member of SHIP he raises the profile for the
Life Sciences Sector in Scotland. Current focus for the Life Sciences ILG is the refresh of the sector strategy to drive growth and Mark is leading on this work to ensure we not only meet, but exceed, our goal of £8Billion generated by the Scottish Life Sciences sector by 2025.
Commercially Mark Chairs the Board on Brain Health Scotland Life Sciences Limited which seeks to widen access to clinical trials in the neurodegenerative disease space. Mark is proud to be able to support the Jane Moore Trust, a charity which provides residential education for young people. Mark is Chairs ABHI Scotland and has published on healthcare resource utilization.

Ayham Alnabulsi is a strategic visionary, an immunologist, geneticist, engineer and mathematician by training. Ayham has over a decade of experience in developing new technologies and building commercial value for life science biotechs. His passion is the development of disruptive transformational technologies to create benefits for the NHS and low/middle-income countries. Ayham has founded and led multiple companies that focused on delivering high-quality products whilst utilising artificial intelligence algorithms to accelerate biotherapeutic, diagnostic and vaccine discovery. More recently, Ayham has co-founded EpitogenX and is the co-inventor of the company's disruptive technologies "EpitoPredikt and EpitoGen".

Rob is co-founder and Head of Life Sciences at Wyoming Interactive, a digital consultancy providing user-centred research & design and custom software development.

Rob works across a variety of sectors within Life Sciences including diagnostics, pharmaceutical manufacturing, clinical trials, and medical devices, helping organisations improve commercial performance through the application of digital technologies.

Our firm takes a data-led approach to performance improvement, helping customers to release value through digital transformation, via quality or yield improvements, process resilience, increasing automation, decarbonisation, and customer engagement & development.

Mark Warne was appointed as Chief Executive of the Deepmatter Group Ltd on 2 July 2018. Mark is widely recognised in the UK and international life sciences sector, having spent almost ten years at IP Group plc, a leading intellectual property commercialisation company, where he led the Healthcare team. He managed a portfolio of £330m of net assets in 2016/17 and represented IP Group on the boards of both listed and private companies. In 2018, concurrent with the integration of Touchstone Innovations into IP Group, Mark became a Partner in the Life Sciences division. He joined IP Group from pre-clinical drug discovery CRO Exelgen, where he was Managing Director. Mark spent eight years at Exelgen (formerly Tripos Discovery Research) where he also held positions in licensing and strategic affairs, project management and research. He has a PhD in Computational Chemistry, an MSc in Colloid Science and a BSc in Chemistry, all from the University of Bristol. Mark is a Chartered Chemist and member of the Royal Society of Chemistry. He serves as a Non-Executive Director on the board of Ixico Plc and as an advisor for Angelini Ventures.

Dr. Dave Berry is Head of Digital Business Systems for CPI’s Pharma facing Centres. He started his career as a pharmacist for the NHS specialising in oncology, completed his PhD and moved to AstraZeneca to develop novel cancer treatments. After his time at AZ he led a research group at Durham University and set up the Complex Powders facility in the National Formulation Centre. Dave is passionate about collaborative innovation and leveraging digital technology to drive the effective development of new medicines.

Specialising in Life Sciences, Alix Mackay provides commercial leadership and strategy for high growth enterprises in biotechnology, health tech and agritech. She has advised CEOs, academic entrepreneurs and innovation centres across the UK and works with key stakeholders including AHSNs, Venture Capital firms and government agencies to help them support their networks. Alix’s career began in the biopharmaceutical industry where she held a number of senior marketing roles including at Amgen where, in a joint venture with GSK, she led the UK launch of a therapeutic monoclonal antibody for the treatment of osteoporosis. Alix is a member of Scotland’s Industry Leadership Group and the Royal Society of Chemistry.

Graham Watson LLB CA FRSA is an experienced non-executive director and senior executive with a strong commercial track record. He has a rich mix of board responsibilities in Scotland, including InnoScot Health, Aurum Biosciences Limited, The Law Society of Scotland, UHI Perth, Tennis Scotland, and Scottish Futures Trust. He is a former partner in a Big 4 accounting firm, with extensive international investment banking experience of working with SME clients, delivering business development and strategic planning programmes and leading change initiatives.

Clare works in the Climate Partnerships team at ECCI, and is Programme Director for the Climate Intelligence Service, working in partnership with the Improvement Service and alongside the Sustainable Scotland Network to support area-wide climate action across Scotland. Clare has worked in the Scottish Climate Change consultancy sector for over 20 years, providing advice and support to public and private sector organisations to help calculate and reduce their embodied and operational emissions. Recently she has worked with City of Edinburgh Council, the Scottish Cities Alliance and the Scottish Government on organisational, area-wide and supply chain solutions, focusing on developing tools and training for both the public and private sectors, as well as supporting SMEs to develop strategies and action plans for transition. She has also developed a variety of carbon management tools, including the Climate Change Assessment Tool and the Climate Change Fund calculators.

After studying a Masters in Sustainability and Management at Royal Holloway, Addie became ABHI's first Sustainability Executive, joining the Association in 2022 to lead on this critical agenda.

Addie provides support to the membership and works with stakeholders to ensure the role of sustainability within HealthTech is recognised. In managing ABHI's Sustainability Group, Addie is helping the industry to tackle the opportunities and challenges that exist on such a complex topic

Dr Claire Garden SFHEA MRSB is an Associate Professor in Life Science Education and Head of
Learning and Teaching at the School of Applied Sciences, Edinburgh Napier University. She has over a
decade of experience delivering responsive upskilling in collaboration with life science companies
and other stakeholders, most recently as the sole Scottish university member of the successful
Advanced Therapies Skills Training Network. Claire is an expert in collaborative, applied life science
curriculum design, chairs the Scottish Universities Life Sciences Alliance Skills Committee and
recently led and organised the inaugural Scottish Life and Chemical Sciences Skills Summit.

Jacqueline Barry is the Chief Clinical Officer for the Cell and Gene Therapy Catapult (CGT), the UK’s centre for the acceleration of the translation of cell therapies towards commercialisation. Before this this Jacqueline was Director of Regulatory at CGT and prior to her time at CGT she worked at the Scottish National Blood Transfusion Service in a number of senior regulatory and quality positions, the responsibility for which included designing the regulatory strategy for the Cellular Therapies developed by the Blood Transfusion Service, acting as Responsible Person for Blood and Qualified Person for medicinal product release. Before that she held a number of post-doctoral academic posts at the University of Edinburgh studying neuromuscular regeneration. She has considerable experience in the development, translation, clinical trial and approval of cell-based medicinal products and therapies.

Matt Shaughnessy is Head of Operations Sustainability, AstraZeneca and has over 30 years’ experience in the Pharmaceutical Industry.

Matt has a degree in Pharmacy and started his career in the hospital setting before moving to the Pharmaceutical Industry. Matt initially worked in R&D on formulation development for new injectable medicines before taking accountability for the manufacture and supply of medicines for clinical trials. Moving to Operations and Supply Chain, Matt has held several leadership roles in Projects, Manufacturing and Logistics. A significant part of Matt’s career in Operations has been spent managing supply chains through third party relationships.

Matt moved into his current role in June 2020 to take accountability for developing and delivering the Sustainability Strategy for AstraZeneca Operations. In addition, Matt’s role also includes the application of Digital, Data Science, Project Management and Lean to sustainability matters across the AstraZeneca Enterprise.

Matt also leads on Sustainability for the Medicines Manufacturing Industrial Partnership (UK Government and Biopharmaceutical industry.

Wendy is a Fellow of the Chartered Institute of Waste Management, a Chartered Environmentalist and a member of the Institute of Environmental Management and Assessment (IEMA) Circular Economy Steering Group. She works for the Scottish Government as Head of Circular Economy for NHS Scotland. She has a broad range of experience including consultancy and working in industry in the UK and internationally.

John is the Director of the Medicines Manufacturing Innovation Centre, Glasgow, a collaboration between CPI, University of Strathclyde, UK Research & Industry, Scottish Enterprise and founding industry partners, AstraZeneca and GSK. The centre will ensure the UK is a technology and innovation leader in pharmaceutical manufacturing, thereby boosting the competitiveness of both sectors. The initial focus will be on technology translation for small molecule drug manufacture. In January 2022, John also became the interim Director of CPI’s Biologics capabilities for 6 months. Prior to joining CPI in October 2019 John worked for GSK, joining the company in 1986 as a Process Chemist at the Worthing Site. During his time on Site he held roles covering all aspects of the manufacturing supply chain from large scale fermentation, fine chemicals (both chemical and enzymatic conversions), Chemical Development and Secondary Sterile Operations. After 10 years of site base roles he was seconded to Head office to lead a workstream of a global supply restructuring programme. In 2000 he moved to the Irvine plant to lead the Development team and take change of the construction a new 300te nanomilling and spray drying plant. This period was followed with a number of roles working out of GSK House in strategic program leadership including Head of the Global Manufacturing & Supply Programme
anagement Office, 5 years in the Core Business Services Function (IT, Procurement and Real estate) as Head of PMO and finally back to manufacturing to Leader a Global manufacturing restructuring programme. John has a BSc (Hons) in Chemistry, an MBA from Strathclyde University Business School, a Private Pilot’s license and double decker bus license.